{"id":745581,"date":"2017-03-06T08:00:00","date_gmt":"2017-03-06T08:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-pfizer-announce-u-s-fda-and-ema-filing-acceptances-of-three-marketing-applications-for-ertugliflozin-containing-medicines-for-adults-with-type-2-diabetes\/"},"modified":"2025-11-07T01:26:38","modified_gmt":"2025-11-07T06:26:38","slug":"merck-and-pfizer-announce-u-s-fda-and-ema-filing-acceptances-of-three-marketing-applications-for-ertugliflozin-containing-medicines-for-adults-with-type-2-diabetes","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-pfizer-announce-u-s-fda-and-ema-filing-acceptances-of-three-marketing-applications-for-ertugliflozin-containing-medicines-for-adults-with-type-2-diabetes\/","title":{"rendered":"Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes"},"content":{"rendered":"<p class=\"bwalignc\">       Investigational SGLT2 Inhibitor Submitted as Monotherapy and in        Fixed-Dose Combinations with JANUVIA <sup> \u00ae <\/sup>         (sitagliptin) or Metformin     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada, and<br \/>\n      Pfizer Inc. (NYSE:FE), today announced that the U.S. Food and Drug<br \/>\n      Administration (FDA) has accepted for review three New Drug Applications<br \/>\n      (NDAs) for medicines containing ertugliflozin, an investigational SGLT2<br \/>\n      inhibitor in development to help improve glycemic control in adults with<br \/>\n      type 2 diabetes: one for monotherapy, one for the fixed-dose combination<br \/>\n      of ertugliflozin and JANUVIA<sup>\u00ae<\/sup> (sitagliptin), and one for the<br \/>\n      fixed-dose combination of ertugliflozin and metformin. The Prescription<br \/>\n      Drug User Fee Act (PDUFA) action date from the FDA is in December 2017<br \/>\n      for the three NDAs. Additionally, the European Medicines Agency (EMA)<br \/>\n      has validated for review three Marketing Authorization Applications<br \/>\n      (MAAs) for ertugliflozin monotherapy and the two fixed-dose combination<br \/>\n      products.\n    <\/p>\n<p>\n      These marketing applications to the FDA and EMA are supported by studies<br \/>\n      in the VERTIS clinical development program of ertugliflozin, including<br \/>\n      VERTIS MONO, VERTIS FACTORIAL, and VERTIS SITA2, which were first<br \/>\n      presented at medical congresses in 2016. The full VERTIS clinical<br \/>\n      development program is comprised of nine Phase 3 trials in approximately<br \/>\n      12,600 adults with type 2 diabetes.\n    <\/p>\n<p>\n      \u201cThe acceptance of the three applications by both the FDA and EMA<br \/>\n      represents an important milestone in the progression of our<br \/>\n      collaboration with Pfizer on ertugliflozin, and reflects Merck\u2019s<br \/>\n      commitment to advancing new treatment options for people with type 2<br \/>\n      diabetes around the world,\u201d said Sam Engel, M.D., associate vice<br \/>\n      president, Merck clinical research, diabetes and endocrinology. \u201cIf<br \/>\n      approved, we believe ertugliflozin will be an important option for many<br \/>\n      patients and a welcome addition to our already strong type 2 diabetes<br \/>\n      portfolio, with our DPP-4 inhibitor JANUVIA as the foundation.\u201d\n    <\/p>\n<p>\n      \u201cBecause type 2 diabetes is a progressive disease, patients may need<br \/>\n      multiple treatment options to help them manage their condition. That is<br \/>\n      why we are proud of the comprehensive VERTIS clinical development<br \/>\n      program, and we look forward to working closely with the FDA and EMA in<br \/>\n      an effort to bring these three additional treatment options to adults<br \/>\n      with type 2 diabetes,\u201d said James Rusnak, M.D., Ph.D., chief development<br \/>\n      officer, cardiovascular and metabolic diseases, Pfizer Global Product<br \/>\n      Development.\n    <\/p>\n<p>\n      <b>Important Information about JANUVIA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b><br \/>\n      (sitagliptin) 25 mg, 50 mg and 100 mg tablets<\/b>\n    <\/p>\n<p>\n      JANUVIA is indicated as an adjunct to diet and exercise to improve<br \/>\n      glycemic control in adults with type 2 diabetes mellitus. JANUVIA should<br \/>\n      not be used in patients with type 1 diabetes or for the treatment of<br \/>\n      diabetic ketoacidosis. JANUVIA has not been studied in patients with a<br \/>\n      history of pancreatitis. It is unknown whether patients with a history<br \/>\n      of pancreatitis are at increased risk of developing pancreatitis while<br \/>\n      taking JANUVIA.\n    <\/p>\n<p>\n      <b>Selected Important Risk Information about JANUVIA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>\n    <\/p>\n<p>\n      JANUVIA is contraindicated in patients with a history of a serious<br \/>\n      hypersensitivity reaction to sitagliptin, such as anaphylaxis or<br \/>\n      angioedema.\n    <\/p>\n<p>\n      There have been postmarketing reports of acute pancreatitis, including<br \/>\n      fatal and nonfatal hemorrhagic or necrotizing pancreatitis, in patients<br \/>\n      taking JANUVIA. After initiating JANUVIA, observe patients carefully for<br \/>\n      signs and symptoms of pancreatitis. If pancreatitis is suspected,<br \/>\n      promptly discontinue JANUVIA and initiate appropriate management. It is<br \/>\n      unknown whether patients with a history of pancreatitis are at increased<br \/>\n      risk of developing pancreatitis while taking JANUVIA.\n    <\/p>\n<p>\n      Assessment of renal function is recommended prior to initiating JANUVIA<br \/>\n      and periodically thereafter. A dosage adjustment is recommended in<br \/>\n      patients with moderate or severe renal insufficiency and in patients<br \/>\n      with end-stage renal disease requiring hemodialysis or peritoneal<br \/>\n      dialysis. Caution should be used to ensure that the correct dose of<br \/>\n      JANUVIA is prescribed.\n    <\/p>\n<p>\n      There have been postmarketing reports of worsening renal function,<br \/>\n      including acute renal failure, sometimes requiring dialysis. A subset of<br \/>\n      these reports involved patients with renal insufficiency, some of whom<br \/>\n      were prescribed inappropriate doses of sitagliptin.\n    <\/p>\n<p>\n      When JANUVIA was used in combination with a sulfonylurea or insulin,<br \/>\n      medications known to cause hypoglycemia, the incidence of hypoglycemia<br \/>\n      was increased over that of placebo. Therefore, a lower dose of<br \/>\n      sulfonylurea or insulin may be required to reduce the risk of<br \/>\n      hypoglycemia.\n    <\/p>\n<p>\n      The incidence (and rate) of hypoglycemia based on all reports of<br \/>\n      symptomatic hypoglycemia were: 12.2% (0.59 episodes\/patient-year) for<br \/>\n      JANUVIA 100 mg in combination with glimepiride (with or without<br \/>\n      metformin), 1.8% (0.24 episodes\/patient-year) for placebo in combination<br \/>\n      with glimepiride (with or without metformin), 15.5% (1.06<br \/>\n      episodes\/patient-year) for JANUVIA 100 mg in combination with insulin<br \/>\n      (with or without metformin), and 7.8% (0.51 episodes\/patient-year) for<br \/>\n      placebo in combination with insulin (with or without metformin).\n    <\/p>\n<p>\n      There have been postmarketing reports of serious hypersensitivity<br \/>\n      reactions in patients treated with JANUVIA, such as anaphylaxis,<br \/>\n      angioedema, and exfoliative skin conditions including Stevens \u2013Johnson<br \/>\n      syndrome. Onset of these reactions occurred within the first 3 months<br \/>\n      after initiation of treatment with JANUVIA, with some reports occurring<br \/>\n      after the first dose. If a hypersensitivity reaction is suspected,<br \/>\n      discontinue JANUVIA, assess for other potential causes for the event,<br \/>\n      and institute alternative treatment for diabetes.\n    <\/p>\n<p>\n      Angioedema has also been reported with other dipeptidyl peptidase-4<br \/>\n      (DPP-4) inhibitors. Use caution in a patient with a history of<br \/>\n      angioedema with another DPP-4 inhibitor because it is unknown whether<br \/>\n      such patients will be predisposed to angioedema with JANUVIA.\n    <\/p>\n<p>\n      There have been postmarketing reports of severe and disabling arthralgia<br \/>\n      in patients taking DPP-4 inhibitors. The time to onset of symptoms<br \/>\n      following initiation of drug therapy varied from 1 day to years.<br \/>\n      Patients experienced relief of symptoms upon discontinuation of the<br \/>\n      medication. A subset of patients experienced a recurrence of symptoms<br \/>\n      when restarting the same drug or a different DPP-4 inhibitor. Consider<br \/>\n      DPP-4 inhibitors as a possible cause for severe joint pain and<br \/>\n      discontinue drug if appropriate.\n    <\/p>\n<p>\n      Postmarketing cases of bullous pemphigoid requiring hospitalization have<br \/>\n      been reported with DPP-4 inhibitor use. In reported cases, patients<br \/>\n      typically recovered with topical or systemic immunosuppressive treatment<br \/>\n      and discontinuation of the DPP-4 inhibitor. Tell patients to report<br \/>\n      development of blisters or erosions while receiving JANUVIA. If bullous<br \/>\n      pemphigoid is suspected, JANUVIA should be discontinued and referral to<br \/>\n      a dermatologist should be considered for diagnosis and appropriate<br \/>\n      treatment.\n    <\/p>\n<p>\n      There have been no clinical studies establishing conclusive evidence of<br \/>\n      macrovascular risk reduction with JANUVIA or with any other antidiabetic<br \/>\n      drug.\n    <\/p>\n<p>\n      In clinical studies, the adverse reactions reported, regardless of<br \/>\n      investigator assessment of causality, in \u22655% of patients treated with<br \/>\n      JANUVIA as monotherapy and in combination therapy and more commonly than<br \/>\n      in patients treated with placebo, were upper respiratory tract<br \/>\n      infection, nasopharyngitis, and headache.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For over a century, Merck has been a global health care leader working<br \/>\n      to help the world be well. Merck is known as MSD outside the United<br \/>\n      States and Canada. Through our prescription medicines, vaccines,<br \/>\n      biologic therapies, and animal health products, we work with customers<br \/>\n      and operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51520398&amp;newsitemid=20170306005393&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=8c71b765f8d833dd71cc480fc82746ca\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51520398&amp;newsitemid=20170306005393&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=58e586743117c02efb5aab5f181241c3\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51520398&amp;newsitemid=20170306005393&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=74736b737544cd67eeb476a0cee3bca9\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51520398&amp;newsitemid=20170306005393&amp;lan=en-US&amp;anchor=YouTube&amp;index=4&amp;md5=01b994213729b047a506e035259b66a3\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51520398&amp;newsitemid=20170306005393&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=260bf4c814804d65862052efc0c85a0f\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>About Pfizer Inc.: Working together for a healthier world<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>\n    <\/p>\n<p>\n      At Pfizer, we apply science and our global resources to bring therapies<br \/>\n      to people that extend and significantly improve their lives. We strive<br \/>\n      to set the standard for quality, safety and value in the discovery,<br \/>\n      development and manufacture of health care products. Our global<br \/>\n      portfolio includes medicines and vaccines as well as many of the world&#8217;s<br \/>\n      best-known consumer health care products. Every day, Pfizer colleagues<br \/>\n      work across developed and emerging markets to advance wellness,<br \/>\n      prevention, treatments and cures that challenge the most feared diseases<br \/>\n      of our time. Consistent with our responsibility as one of the world&#8217;s<br \/>\n      premier innovative biopharmaceutical companies, we collaborate with<br \/>\n      health care providers, governments and local communities to support and<br \/>\n      expand access to reliable, affordable health care around the world. For<br \/>\n      more than 150 years, we have worked to make a difference for all who<br \/>\n      rely on us. We routinely post information that may be important to<br \/>\n      investors on our website at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.pfizer.com%2F&amp;esheet=51520398&amp;newsitemid=20170306005393&amp;lan=en-US&amp;anchor=www.pfizer.com&amp;index=6&amp;md5=77ddd8df8336be1442cdd1d7f84cd0d6\" rel=\"nofollow\">www.pfizer.com<\/a>.<br \/>\n      In addition, to learn more, please visit us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.pfizer.com%2F&amp;esheet=51520398&amp;newsitemid=20170306005393&amp;lan=en-US&amp;anchor=www.pfizer.com&amp;index=7&amp;md5=1e2f678dc8afba513d5563e94796b91b\" rel=\"nofollow\">www.pfizer.com<\/a><br \/>\n      and follow us on Twitter at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fpfizer&amp;esheet=51520398&amp;newsitemid=20170306005393&amp;lan=en-US&amp;anchor=%40Pfizer&amp;index=8&amp;md5=6870eb7d9ceac8738823942ea58eff7b\" rel=\"nofollow\">@Pfizer<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fpfizer_news&amp;esheet=51520398&amp;newsitemid=20170306005393&amp;lan=en-US&amp;anchor=%40PfizerNews&amp;index=9&amp;md5=46d1fc43a4694b9b71a2b00aec32c016\" rel=\"nofollow\">@PfizerNews<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fpfizer&amp;esheet=51520398&amp;newsitemid=20170306005393&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=10&amp;md5=2de9ee7d72b2e86f41430669286bb6cc\" rel=\"nofollow\">LinkedIn<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fpfizer&amp;esheet=51520398&amp;newsitemid=20170306005393&amp;lan=en-US&amp;anchor=YouTube&amp;index=11&amp;md5=ee06cf74fad5e07d586facc71c944d14\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and like us on Facebook at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FPfizer%2F&amp;esheet=51520398&amp;newsitemid=20170306005393&amp;lan=en-US&amp;anchor=Facebook.com%2FPfizer&amp;index=12&amp;md5=9352b37ccadbda2fec31b91d68449e47\" rel=\"nofollow\">Facebook.com\/Pfizer<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51520398&amp;newsitemid=20170306005393&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=13&amp;md5=126fa20f584fa41c50b0fe8b6d18fa50\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Pfizer Disclosure Notice<\/b>\n    <\/p>\n<p>\n      The information contained in this release is as of March 6, 2017. Pfizer<br \/>\n      assumes no obligation to update forward-looking statements contained in<br \/>\n      this release as the result of new information or future events or<br \/>\n      developments.\n    <\/p>\n<p>\n      This release contains forward-looking information about a product<br \/>\n      candidate, ertugliflozin, and applications submitted to the FDA and the<br \/>\n      EMA for monotherapy and fixed-dose combinations, including their<br \/>\n      potential benefits, that involves substantial risks and uncertainties<br \/>\n      that could cause actual results to differ materially from those<br \/>\n      expressed or implied by such statements. Risks and uncertainties<br \/>\n      include, among other things, the uncertainties inherent in research and<br \/>\n      development, including the ability to meet anticipated trial<br \/>\n      commencement and completion dates and regulatory submission dates, as<br \/>\n      well as the possibility of unfavorable clinical trial results, including<br \/>\n      unfavorable new clinical data and additional analyses of existing<br \/>\n      clinical data; whether and when any applications for ertugliflozin may<br \/>\n      be filed with regulatory authorities in any other jurisdictions; whether<br \/>\n      and when the FDA and EMA may approve the pending applications and<br \/>\n      whether and when regulatory authorities in any other jurisdictions may<br \/>\n      approve any such other applications, which will depend on the assessment<br \/>\n      by such regulatory authorities of the benefit-risk profile suggested by<br \/>\n      the totality of the efficacy and safety information submitted; decisions<br \/>\n      by regulatory authorities regarding labeling and other matters that<br \/>\n      could affect the availability or commercial potential of ertugliflozin<br \/>\n      in monotherapy or in fixed-dose combination; and competitive<br \/>\n      developments. The competitive landscape for type 2 diabetes therapies,<br \/>\n      including SGLT2 inhibitors, continues to evolve. The success of our<br \/>\n      ertugliflozin program is dependent on developments in that space.\n    <\/p>\n<p>\n      A further description of risks and uncertainties can be found in<br \/>\n      Pfizer\u2019s Annual Report on Form 10-K for the fiscal year ended December<br \/>\n      31, 2016 and in its subsequent reports on Form 10-Q, including in the<br \/>\n      sections thereof captioned \u201cRisk Factors\u201d and \u201cForward-Looking<br \/>\n      Information and Factors That May Affect Future Results\u201d, as well as in<br \/>\n      its subsequent reports on Form 8-K, all of which are filed with the U.S.<br \/>\n      Securities and Exchange Commission and available at&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51520398&amp;newsitemid=20170306005393&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=14&amp;md5=100dc6b731e374d2ea91c61dd2151b66\" rel=\"nofollow\">www.sec.gov<\/a>&nbsp;and&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.pfizer.com%2F&amp;esheet=51520398&amp;newsitemid=20170306005393&amp;lan=en-US&amp;anchor=www.pfizer.com&amp;index=15&amp;md5=9331043baa42e3b03935e70e0f526edb\" rel=\"nofollow\">www.pfizer.com<\/a>.\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for JANUVIA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b><br \/>\n      (sitagliptin) at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fj%2Fjanuvia%2Fjanuvia_pi.pdf&amp;esheet=51520398&amp;newsitemid=20170306005393&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fj%2Fjanuvia%2Fjanuvia_pi.pdf&amp;index=16&amp;md5=ab84935d1a4bad54f0e0ea3c791a0830\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/j\/januvia\/januvia_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b><br \/>\n      and Medication Guide for JANUVIA at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fj%2Fjanuvia%2Fjanuvia_mg.pdf&amp;esheet=51520398&amp;newsitemid=20170306005393&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fj%2Fjanuvia%2Fjanuvia_mg.pdf&amp;index=17&amp;md5=c5614f209a0a73d02dceb1066f12027c\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/j\/januvia\/januvia_mg.pdf<\/b><br \/>\n<\/a>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170306005393r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck Media:<br \/>Doris Li, (908) 246-5701<br \/>or<br \/>Merck Investor:<br \/>Amy        Klug, (908) 740-1898<br \/>or<br \/>Kristen Drake, (908) 236-4223<br \/>or<br \/>Pfizer        Media:<br \/>Steve Danehy, (212) 733-1538<br \/>or<br \/>Pfizer Investor:<br \/>Ryan        Crowe, (212) 733-8160     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Investigational SGLT2 Inhibitor Submitted as Monotherapy and in Fixed-Dose Combinations with JANUVIA \u00ae (sitagliptin) or Metformin Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:FE), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review three New Drug Applications (NDAs) for medicines containing ertugliflozin, an investigational SGLT2 inhibitor in development to help improve glycemic control in adults with type 2 diabetes: one for monotherapy, one for the fixed-dose combination of ertugliflozin and JANUVIA\u00ae (sitagliptin), and one for the fixed-dose combination of ertugliflozin and metformin. The Prescription Drug User Fee Act (PDUFA) action date from the FDA is in December 2017 for the three NDAs. Additionally, the European Medicines Agency (EMA) has validated for review three Marketing Authorization Applications (MAAs) for ertugliflozin monotherapy and the two fixed-dose combination products. These<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-745581","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-pfizer-announce-u-s-fda-and-ema-filing-acceptances-of-three-marketing-applications-for-ertugliflozin-containing-medicines-for-adults-with-type-2-diabetes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Investigational SGLT2 Inhibitor Submitted as Monotherapy and in Fixed-Dose Combinations with JANUVIA \u00ae (sitagliptin) or Metformin Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:FE), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review three New Drug Applications (NDAs) for medicines containing ertugliflozin, an investigational SGLT2 inhibitor in development to help improve glycemic control in adults with type 2 diabetes: one for monotherapy, one for the fixed-dose combination of ertugliflozin and JANUVIA\u00ae (sitagliptin), and one for the fixed-dose combination of ertugliflozin and metformin. The Prescription Drug User Fee Act (PDUFA) action date from the FDA is in December 2017 for the three NDAs. Additionally, the European Medicines Agency (EMA) has validated for review three Marketing Authorization Applications (MAAs) for ertugliflozin monotherapy and the two fixed-dose combination products. These\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-pfizer-announce-u-s-fda-and-ema-filing-acceptances-of-three-marketing-applications-for-ertugliflozin-containing-medicines-for-adults-with-type-2-diabetes\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-pfizer-announce-u-s-fda-and-ema-filing-acceptances-of-three-marketing-applications-for-ertugliflozin-containing-medicines-for-adults-with-type-2-diabetes\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-pfizer-announce-u-s-fda-and-ema-filing-acceptances-of-three-marketing-applications-for-ertugliflozin-containing-medicines-for-adults-with-type-2-diabetes\\\/\",\"name\":\"Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-03-06T08:00:00+00:00\",\"dateModified\":\"2025-11-07T06:26:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-pfizer-announce-u-s-fda-and-ema-filing-acceptances-of-three-marketing-applications-for-ertugliflozin-containing-medicines-for-adults-with-type-2-diabetes\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-pfizer-announce-u-s-fda-and-ema-filing-acceptances-of-three-marketing-applications-for-ertugliflozin-containing-medicines-for-adults-with-type-2-diabetes\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-pfizer-announce-u-s-fda-and-ema-filing-acceptances-of-three-marketing-applications-for-ertugliflozin-containing-medicines-for-adults-with-type-2-diabetes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-pfizer-announce-u-s-fda-and-ema-filing-acceptances-of-three-marketing-applications-for-ertugliflozin-containing-medicines-for-adults-with-type-2-diabetes\/","og_locale":"en_US","og_type":"article","og_title":"Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes - Merck.com","og_description":"Investigational SGLT2 Inhibitor Submitted as Monotherapy and in Fixed-Dose Combinations with JANUVIA \u00ae (sitagliptin) or Metformin Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:FE), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review three New Drug Applications (NDAs) for medicines containing ertugliflozin, an investigational SGLT2 inhibitor in development to help improve glycemic control in adults with type 2 diabetes: one for monotherapy, one for the fixed-dose combination of ertugliflozin and JANUVIA\u00ae (sitagliptin), and one for the fixed-dose combination of ertugliflozin and metformin. The Prescription Drug User Fee Act (PDUFA) action date from the FDA is in December 2017 for the three NDAs. Additionally, the European Medicines Agency (EMA) has validated for review three Marketing Authorization Applications (MAAs) for ertugliflozin monotherapy and the two fixed-dose combination products. These","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-pfizer-announce-u-s-fda-and-ema-filing-acceptances-of-three-marketing-applications-for-ertugliflozin-containing-medicines-for-adults-with-type-2-diabetes\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:38+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-pfizer-announce-u-s-fda-and-ema-filing-acceptances-of-three-marketing-applications-for-ertugliflozin-containing-medicines-for-adults-with-type-2-diabetes\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-pfizer-announce-u-s-fda-and-ema-filing-acceptances-of-three-marketing-applications-for-ertugliflozin-containing-medicines-for-adults-with-type-2-diabetes\/","name":"Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-03-06T08:00:00+00:00","dateModified":"2025-11-07T06:26:38+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-pfizer-announce-u-s-fda-and-ema-filing-acceptances-of-three-marketing-applications-for-ertugliflozin-containing-medicines-for-adults-with-type-2-diabetes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-pfizer-announce-u-s-fda-and-ema-filing-acceptances-of-three-marketing-applications-for-ertugliflozin-containing-medicines-for-adults-with-type-2-diabetes\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-pfizer-announce-u-s-fda-and-ema-filing-acceptances-of-three-marketing-applications-for-ertugliflozin-containing-medicines-for-adults-with-type-2-diabetes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"bc92ff5a-b1b7-4440-ad9e-7c9c11499827","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2017\/03\/1\/merck_logo.jpg","size":"21167","File Upload":""},{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2017\/03\/1\/orig1669106_Pfizer_logo.jpg","size":"48264","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-and-Pfizer-Announce-US-FDA-and-EMA-Filing-Acceptances-of-Three-Marketing-Applications-for-Ertugliflozin-Containing-Medicines-fo-2MU89.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745581","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":2,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745581\/revisions"}],"predecessor-version":[{"id":3674952,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745581\/revisions\/3674952"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745581"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}